Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2

Fabio Bachmann1,2, Urs Duthaler1,2, Henriette E. Meyer zu Schwabedissen3, Maxim Puchkov4, Jörg Huwyler4, Manuel Haschke5,6 and Stephan Krähenbühl1,2,*

Metamizole is an analgesic and antipyretic drug used intensively in certain countries. Previous studies have shown that metamizole induces cytochrome (CYP) 2B6 and possibly CYP3A4. So far, it is unknown whether metamizole induces additional CYPs and by which mechanism. Therefore, we assessed the activity of 6 different CYPs in 12 healthy male subjects before and after treatment with 3 g of metamizole per day for 1 week using a phenotyping cocktail approach. In addition, we investigated whether metamizole induces CYPs by an interaction with the constitutive androstane receptor (CAR) or the pregnane X receptor (PXR) in HepaRG cells. In the clinical study, we confirmed a moderate induction of CYP2B6 (decrease in the efavirenz area under the plasma concentration time curve (AUC) by 79%) and 3A4 (decrease in the midazolam AUC by 68%) by metamizole. In addition, metamizole weakly induced CYP2C9 (decrease in the flurbiprofen AUC by 22%) and moderately CYP2C19 (decrease in the omeprazole AUC by 66%) but did not alter CYP2D6 activity. In addition, metamizole weakly inhibited CYP1A2 activity (1.79-fold increase in the caffeine AUC). We confirmed these results in HepaRG cells, where 4-MAA, the principal metabolite of metamizole, induced the mRNA expression of CYP2B6, 2C9, 2C19, and 3A4. In HepaRG cells with a stable knockout of PXR or CAR, we could demonstrate that CYP induction by 4-MAA depends on CAR and not on PXR. In conclusion, metamizole is a broad CYP inducer by an interaction with CAR and an inhibitor of CYP1A2. Regarding the widespread use of metamizole, these findings are of substantial clinical relevance.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
☑ Several studies indicate that metamizole is an inducer of CYP2B6 and CYP3A4. However, no studies have so far been conducted to elucidate the interaction potential of metamizole for other CYPs. Furthermore, the mechanism of induction is currently not known.

WHAT QUESTION DID THIS STUDY ADDRESS?
☑ This study addressed the influence of metamizole on the activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4 in healthy volunteers. Additionally, in vitro experiments were conducted to explore the mechanism of CYP induction.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
☑ The results of the clinical study show that metamizole weakly inhibits the activity of CYP1A2 and moderately induces CYP2B6, CYP2C19, and CYP3A4 and weakly induces CYP2C9. Interaction with the constitutive androstane receptor is needed for the induction for CYP induction.

HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY AND TRANSLATIONAL SCIENCE?
☑ This study adds valuable information about the drug-drug interaction potential of metamizole. Because metamizole is often also used in the geriatric population with a high prevalence of polypharmacy, this information is clinically important.

Metamizole (dipyrone) is an old drug with analgesic, antipyretic, and spasmylytic properties. In Germany and Switzerland, metamizole is prescribed frequently because of its favorable gastrointestinal and renal tolerability compared with nonsteroidal anti-inflammatory drugs, while exhibiting a similar analgesic and antipyretic activity.1–4 Metamizole is a prodrug, which, after oral application, is spontaneously hydrolyzed in the intestinal tract to N-methyl-4-aminoantipyrine (4-MAA).5 The 4-MAA is the major metabolite in plasma, which is demethylated to 4-aminoantipyrine (4-AA) or oxidized to...
4-formylaminoantipyrine, an end metabolite. Furthermore, 4-AA is acetylated by N-acetyltransferase 2 to 4-acetylaminoantipyrine, another end metabolite. \(^6\)–\(^{12}\) The metabolic pathway of metamizole is illustrated in Figure 1. The enzymes responsible for the demethylation and the oxidation of 4-MAA have so far not been conclusively identified. The prolonged half-life of 4-MAA in patients with impaired liver function suggests hepatic metabolism of 4-MAA with CYP3A4 as the most important CYP for N-demethylation. \(^9\),\(^{12}\),\(^{13}\) However, extrahepatic metabolism by myeloperoxidase in neutrophil granulocytes has also been described. \(^14\)

Several studies in humans have shown that metamizole can induce specific CYP enzymes. In liver microsomes extracted from biopsies of patients having been treated with metamizole, Saussele et al. showed that protein content and activity of CYP2B6 and CYP3A4 were increased compared with patients not treated with metamizole. \(^{15}\) Moreover, they showed that both 4-MAA and 4-AA increased the protein expression of CYP2B6 and CYP3A4 in primary human hepatocytes without directly interacting with the constitutive androstane (CAR) or the pregnane X receptor (PXR). Because these two nuclear receptors mediate induction of CYP2B6 and CYP3A4 along with other CYPs, \(^{16}\),\(^{17}\) the mechanism of the metamizole derived CYP3A4 and CYP2B6 induction is currently unknown. Qin and colleagues confirmed CYP2B6 induction in healthy volunteers treated with 1.5 g metamizole per day for 4 days, as they observed a 2.1-fold increase in the bupropion hydroxylase activity after metamizole intake. \(^{18}\) Caraco et al. reported that the administration of metamizole decreased cyclosporine blood concentrations in patients after organ transplantation, suggesting CYP3A4 induction. \(^{19}\) Finally, Gaebler et al. found in a retrospective study that patients treated with metamizole had 67% lower sertraline plasma concentrations than patients without metamizole, suggesting CYP2B6 and CYP3A4 induction by metamizole. \(^{20}\) Whereas the currently available studies suggest that metamizole is associated with CYP2B6 and possibly CYP3A4 induction, it remains unclear whether metamizole influences also other CYPs and which is the mechanism of CYP induction.

The interaction of a compound with CYPs can be investigated by a phenotyping cocktail approach, whereby specific substrates of CYPs are administered at subtherapeutic doses to quantify the metabolic activity of selected CYPs. \(^{21}\) The “Basel phenotyping cocktail,” containing specific substrates for CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (flurbiprofen), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam), has been proven to be a reliable tool to determine CYP inhibition as well as CYP induction. \(^{22}\)–\(^{24}\) We therefore treated healthy subjects with metamizole and determined CYP activities before and after 7 days of metamizole ingestion (3 grams per day). Furthermore,
we assessed the effect of 4-MAA on CYP induction and inhibition in wild type HepaRG cells and the interaction of 4-MAA with PXR and CAR using PXR or CAR knock-out HepaRG cells.

**MATERIALS AND METHODS**

**Clinical study**
We conducted a single center, open-label phase I study (clinicaltrials.gov, ID: NCT03990129) with healthy male White volunteers. The study was approved by the ethics committee EKZN (Ethikkommission Nordwestschweiz/Zentral Schweiz) and conducted in accordance with good clinical practice guidelines and the current version of the Declaration of Helsinki.

Healthy male volunteers were screened for any underlying diseases (physical examination, routine laboratory, and electrocardiogram). The use of known enzyme inducers (e.g., St. John’s Wort) or inhibitors (e.g., grapefruit juice) within 2 weeks before study start was an exclusion criterion as well as excessive caffeine consumption, smoking (>5 cigarettes per day) and use of over-the-counter medication.

After signing the informed consent, 12 healthy subjects were included (mean age: 25.0 years, range 21–28 years, mean body mass index: 22.9 kg/m², range 19.7–26.3 kg/m²) into the study. A venous blood sample was drawn to determine routine laboratory parameters and the subjects’ CYP2B6, CYP2C9, CYP2C19, and CYP2D6 genotype. The subjects had to stop consuming caffeine containing nutrients 12 hours prior to both phenotyping cocktail administrations. For the baseline assessment of CYP activity, the subjects fasted overnight and arrived in the morning at the trial site. Prior to treatment, a blood sample was withdrawn from a venous catheter, placed in the non-dominant forearm, to determine the baseline drug concentrations of the subjects. Afterward, the Basler phenotyping cocktail capsule was administered containing 10 mg caffeine (CYP1A2 substrate), 2 mg midazolam (3A4 substrate), 50 mg efavirenz (CYP2B6 substrate), 12.5 mg flurbiprofen (CYP2C9 substrate), 10 mg omeprazole (CYP2C19 substrate), and 12.5 mg metoprolol tartrate (CYP2D6 substrate). Venous blood samples were withdrawn 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, and 24 hours after cocktail administration into EDTA coated tubes. Samples were centrifuged at 1,500 g for 10 minutes at 4°C and the plasma was stored at −80°C until analysis. On the second study day, the subjects began to take 3 times per day 1 g metamizole (2 Novalgin ® 500 mg tablets) for 7 consecutive days. On study day 8, in the morning, the subjects received for a second time the Basel phenotyping cocktail capsule, while metamizole administrations were continued until the afternoon to capture also potential CYP inhibition. The CYP phenotyping procedure was executed as on day 1.

To review compliance with metamizole treatment, subjects had to document their drug intake in a pill-counting journal and had to return the remaining tablets as well as the empty blisters. In addition, plasma levels of metamizole and its metabolites were obtained and prepared as published before. Materials and reagents for the cell culture were ordered and used according to the protocols of a previous publication.

**Bioanalysis**
The analytes were quantified in plasma by high performance liquid chromatography (Shimadzu, Kyoto, Japan) tandem mass spectrometry (ABSciex, Ontario, Canada). Analyses of the Basler phenotyping cocktail substrates and metabolites was conducted as described previously using an API 5500 Qtrap mass spectrometer. An API 4000 mass spectrometer was used to analyze the metabolites of metamizole according to a fully validated method. Data were processed using Analyst software 1.6.2 (ABSciex, Ontario, Canada).

**Cell culture**
All cells were grown at 37°C in a humidified 5% CO₂ cell culture incubator. HepaRG cells (Lot: 1964151) were purchased from Thermo Fisher Scientific (Wohlen, Switzerland). HepaRG cells were counted with the EVE Automatic Cell counter and seeded at 300,000 cells well into 6-well plates. They were cultured and differentiated as previously described. For induction assays, cells were treated for 72 hours with 300 µM 4-MAA, 10 µM rifampicin, 2 mM metformin, or combinations of 4-MAA/metformin (300 µM/2 mM) and rifampicin/metformin (10 µM/2 mM). The vehicle concentration was 0.2% DMSO. During the induction assays, the medium containing the drugs was replaced every 24 hours.

The hPXR-knockout HepaRG cells (Lot: 153429), hCAR-knockout HepaRG cells (Lot: 151345), and 5-F control HepaRG cells (Lot: 208137) were purchased from Sigma-Aldrich (Buchs, Switzerland). Culture and differentiation conditions were similar as described above, except that cell passaging required trypsin 0.25% (Thermo Fisher Scientific, Wohlen, Switzerland) instead of Tryple and the medium was changed trice instead of twice a week. After differentiation, all cells were incubated for 72 hours with 300 µM 4-MAA, or selective inducers (hPXR-knockout: 10 µM rifampicin, hCAR-knockout: 1 µM 6-(4-chlorophenyl)imidazo[2,1-$\beta$][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO; Sigma-Aldrich), and 5-F control: 10 µM rifampicin and 1 µM CITCO). Fresh medium was replenished every 24 hours.

**mRNA quantification**
After induction, cells were harvested and mRNA was extracted and purified using Qiagen RNeasy Mini Extraction kit (Qiagen, Hilden, Germany). The mRNA quantity and quality were determined with a NanoDrop 2000 UV-Vis spectrophotometer (Thermo Fisher Scientific, Germany). cDNA was synthesized with the Qiagen Omniscript system using 0.2–1 µg mRNA. Amplification reactions were performed in triplicate using SYBR green (Roche Diagnostics, Rotkreuz, Switzerland). Primers are listed in the Supplementary Table S1. Real-time polymerase chain reaction was performed on a ViiA 7 Real-Time polymerase chain reaction system (Applied Biosystems, Bedord, MA) and the relative quantity of specifically amplified cDNA was assessed using the comparative-threshold-fold change method. Glyceraldehyde 3-phosphate dehydrogenase served as endogenous reference and no-template and no-reverse-transcription controls confirmed the absence of unspecific amplification.

**Pharmacokinetic calculations and statistics**
The primary end point of the study was the effect of metamizole treatment on the metabolic activity of CYP 1A2, 2A4, 2B6, 2C9, 2C19, and 2D6. CYP activity was determined by quantifying the
### Table 1 Effect of metamizole on the pharmacokinetics and the metabolic ratios of the substrates contained in the Basel phenotyping cocktail

| Substrate        | Basal | Post-treatment | Basal metabolic ratio | Post-treatment metabolic ratio | Basal 1/2 [h] | Post-treatment 1/2 [h] |
|------------------|-------|----------------|-----------------------|-------------------------------|---------------|------------------------|
| **AUC_{inf} [µg × h/L]** |       |                |                       |                               |               |                        |
| Caffeine         | 7211  (5,793–8,977) | 12,912** (8,001–20,836) | 1.54 (1.21–1.97) | 2.80** (1.77–4.42) | 5.02 (4.21–6.00) | 8.60* (5.48–13.5) |
| Paraxanthine     | 4,676 (3,817–5,728) | 4,618 (3,113–6,853) |                       |                               |               |                        |
| Efavirenz        | 3,978 (2,926–5,408) | 821*** (591–1,411) | 90.4 (53.3–153) | 13.9*** (9.65–19.0) | 37.8 (24.6–58.0) | 15.2** (10.4–22.3) |
| 8’-hydroxyefavirenz | 44.0 (31.5–61.6) | 59.3 (40.3–87.2) |                       |                               |               |                        |
| Flurbiprofen     | 10,015 (7,751–12,941) | 7,779*** (5,847–10,350) | 13.8 (8.71–21.9) | 12.2* (7.40–20.3) | 6.35 (5.08–7.94) | 5.21*** (3.92–6.91) |
| 4’-hydroxyflurbiprofen | 726 (561–939) | 636** (487–830) |                       |                               |               |                        |
| Omeprazole       | 187 (138–253) | 62.9*** (45.4–86.9) | 0.84 (0.63–1.12) | 0.42*** (0.30–0.57) | 0.74 (0.63–0.86) | 0.75 (0.66–0.85) |
| 5’-hydroxyomeprazole | 222 (197–252) | 152*** (127–181) |                       |                               |               |                        |
| Metoprolol       | 41.4 (28.0–61.2) | 28.3* (17.1–46.8) | 0.57 (0.37–0.91) | 0.55 (0.33–1.91) | 3.64 (3.10–4.26) | 3.40 (2.76–4.15) |
| α-hydroxymetoprolol | 72.0 (62.4–83.0) | 51.7** (46.1–58.0) |                       |                               |               |                        |
| Midazolam        | 19.7 (14.6–26.7) | 6.25** (3.54–11.0) | 0.40 (0.28–0.57) | 0.10*** (0.06–0.19) | 2.44 (2.03–2.94) | 1.60** (1.23–2.06) |
| 1’-hydroxymidazolam | 49.0 (41.3–58.0) | 59.7* (50.4–70.6) |                       |                               |               |                        |

Twelve healthy subjects were treated with a capsule of the Basel phenotyping cocktail containing caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, and midazolam before and at the end of treatment with metamizole (3 × 1 g per day for 7 days). Numbers represent the geometric mean, while the 95% confidence interval of the geometric mean is represented in brackets.

AUC, area under the curve, 1/2, half-life.

*P < 0.05, **P < 0.01, and ***P < 0.001 vs. values before treatment with metamizole (basal).
following reactions: 1A2: caffeine to paraxanthine, 2B6: efavirenz to 8′-hydroxyefavirenz, 2C9: flurbiprofen to 4′-hydroxyflurbiprofen, 2C19: omeprazole to 5′-hydroxymetoprolol, 2D6: metoprolol to α-hydroxymetoprolol, 3A4: midazolam to 1′-hydroxymidazolam. The metabolic ratio (MR) was used as a measure for the individual CYP activity and calculated by dividing the area under the plasma concentration time curve to infinity (AUCinf) of the probe drug by the AUCinf of the corresponding metabolite. Caffeine and paraxanthine plasma concentrations were corrected because both were present in the baseline samples of every subject. The lowest concentration within the first 2 hours (t0−2h) postdosing was set as the basal concentration C0. We determined the individual elimination rate constant (k), calculated the residual concentration (Cresidual) for every time point with the formula:

\[ C_{\text{residual}} = C_0 \times e^{-k \cdot \Delta t} \]  

(1)

and subtracted the respective residual concentration from the measured concentration at each time point.

AUCmax, maximal plasma concentration (Cmax), terminal half-life (t1/2), and k of the cocktail drugs before and after treatment with metamizole were estimated with the noncompartmental methods using PKanalix (version 2019R1; Lixoft SAS, Abtany, France). AUCs were determined using the linear log trapezoidal method. The elimination rate constant was estimated using linear regression of log concentrations and time. MR, t1/2 and AUCinf of the parent drugs were compared before and after metamizole treatment by the nonparametric Wilcoxon signed-rank test. In vitro conditions in different HepaRG cell systems were compared using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. GraphPad Prism 8 (GraphPad Software, La Jolla, CA) was used for both analyses. A P value of < 0.05 was considered as statistically significant (*: < 0.05, **: < 0.01, ***: < 0.001, and ****: < 0.0001).

RESULTS

Bioanalysis

As shown in the supplement, the analysis of the substrates and the metabolites of the Basel phenotyping cocktail as well as the metamizole metabolites met the criteria specified by the US Food and Drug Administration (FDA) guidelines for the bioanalysis of study samples.35

Compliance

Inspection of the pill-counting journals and evaluation of the remaining tablets and the empty blisters suggested that all the subjects were compliant to the metamizole treatment regimen. Furthermore, as shown in Figure S1, trough levels of the metamizole metabolites determined during and at the end of the study were detectable in all subjects. In comparison to a previous study with the same metamizole dosage in healthy subjects,25 the plasma concentration of all metabolites of the current were either above or within the trough concentration range of the previous study. Based on these results we assumed that the subjects were compliant to the metamizole treatment.

Effect of metamizole on plasma concentrations, AUC, and MR of CYP substrates

The average plasma concentration-time curves of the 6 CYP probe drugs and their CYP-specific metabolites are shown in Figure 2 and the corresponding pharmacokinetic parameters are listed in Table 1. The individual AUCs and the t1/2 of the probe drugs are displayed in Figure S2 and Figure S3, respectively.

All subjects had residual caffeine and paraxanthine in their plasma, because they were allowed to consume caffeine-containing beverages up to 12 hours before the study days 1 and 8. Therefore, the caffeine and paraxanthine baseline levels were calculated using Eq. 1 and subtracted from the respective measured plasma concentrations to isolate the effect of 1A2 phenotyping. High caffeine and paraxanthine levels were observed in 24-hour samples of 3 subjects, indicating that these subjects had consumed caffeine between 12 and 24 hours post-treatment. These 24 hour values were excluded from the analysis and the corresponding 24 hour time points were calculated using Eq. 1. Metamizole delayed the conversion of caffeine to paraxanthine, leading to a 1.79-fold increase in the caffeine AUCinf whereas the AUCinf of paraxanthine was not significantly affected. In contrast to caffeine, metamizole decreased the elimination t1/2 for efavirenz and reduced the AUCinf by 79%. The AUCinf of 8′-hydroxyefavirenz, the principal metabolite formed by CYP2B6, was increased by 34%. Because 4′-hydroxyflurbiprofen, the principal metabolite of flurbiprofen formed by CYP2C9, can be glucuronidated,36 we determined 4′-hydroxyflurbiprofen after deglucuronidation. Metamizole decreased the elimination t1/2 and the AUCinf of flurbiprofen by 22% and the AUCinf of 4′-hydroxyflurbiprofen by 12%. Regarding omeprazole, the probe drug for CYP2C19, metamizole had no significant impact on the elimination velocity but decreased the AUCinf by 66% and for 5′-hydroxymetoprolol by 32%. Metamizole did not significantly affect the elimination velocity of metoprolol, the probe drug for CYP2D6, but decreased the AUCinf by 32% and of α-hydroxymetoprolol by 28%. The decrease in the AUCinf of metoprolol and α-hydroxymetoprolol is most likely explained by the observation that CYP3A4, 2B6, and 2C9, which are induced by metamizole, contribute to O-demethylation and N-dealkylation of metoprolol.37 Metamizole decreased the elimination t1/2 of the CYP3A4 substrate midazolam and its AUCinf by 68% and increased the AUCinf of 1′-hydroxymidazolam (determined after deglucuronidation) by 22%.

The individual metabolic ratios are displayed in Figure 3. For CYP1A2, we found a significant increase in the caffeine:paraxanthine MR with metamizole, indicating inhibition (P = 0.0024). We found a reduction in the efavirenz:8′-hydroxyefavirenz MR from 90.4 to 13.9, demonstrating CYP2B6 induction by metamizole (P = 0.0005). Similarly, metamizole lowered the flurbiprofen:4′-hydroxyflurbiprofen MR (from 13.8 to 12.2), indicating CYP2C9 induction (P = 0.0342). Furthermore, metamizole reduced the MR of omeprazole to 5′-hydroxymetoprolol by ~ 50% (P = 0.0005), demonstrating CYP2C19 induction. CYP2D6 is described in the literature as not inducible.22 In agreement with this notion, we observed no significant change in the MR of metoprolol by metamizole. In contrast, CYP3A4 activity was induced by metamizole as demonstrated by the decrease in the midazolam:1′-hydroxymidazolam MR from 0.40 to 0.10 (P = 0.0005).

Genotype, inducibility, and phenotype correlation

All subjects were analyzed for the SNPs CYP1A2*1F; CYP2B6*6; CYP2C9*2, *3; CYP2C19*2, *17; CYP2D6*2, *3, *4, *6, *9, *10, *17, *29, and *41 in order to identify poor metabolizers (PMs),
intermediate metabolizers (IMs), normal metabolizers (NMs), rapid metabolizers (RMs), and ultra-rapid metabolizers (UM) for the respective CYPs and to investigate their influence on the phenotyping results. The individual values are displayed in Table S2.

To judge a possible effect of the genotype on inducibility, we calculated the ratio of MR – Metamizole : MR + Metamizole and correlated the values with the genotype of the subjects (Figure 4). The relationship between genotype and the basal MR is shown in Figure S4. Five subjects were homozygous for CYP1A2*1F (classified as NM/UM), a genotype associated with higher inducibility of CYP1A2, for instance in smokers. Because we did not include heavy smokers, we did not expect an impact of *1F genotype on the MR of caffeine. The data illustrated in Figure S4 confirmed this assumption. Carriers of the CYP1A2*1F genotype showed a similar distribution of the MR–Metamizole : MR+Metamizole ratio as wild types (Figure 4), indicating that the *1F genotype did not affect CYP1A2 inhibition by metamizole. CYP2B6*6 is associated with impaired efavirenz metabolism. The population studied included eight heterozygous (*1/*6) and four wild-type allele carriers (*1/*1), categorized as IM and NM, respectively. Considering the genotype-phenotype
Figure 3  Metabolic ratios of the six substrates contained in the Basel phenotyping cocktail before and at the end of treatment with metamizole. Healthy subjects (n = 12) were treated with a capsule of the Basel phenotyping cocktail containing caffeine (1A2), efavirenz (2B6), flurbiprofen (2C9), omeprazole (2C19), metoprolol (2D6), and midazolam (3A4) before and at the end of treatment with metamizole (3 × 1 g per day for 7 days). Plasma concentrations were determined using liquid chromatography tandem mass spectrometry. Metabolic ratios were calculated as the area under the plasma concentration time curve to infinity (AUC_{inf}) of the parent drug divided by the AUC_{inf} of the CYP-specific metabolite. Data represent individual values before (-Metamizole, white circles) and after (+ Metamizole, black circles) treatment with metamizole. The black line corresponds to the geometric mean. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. values before treatment with metamizole (baseline).
correlation in the basal state, the MR of NM and IM were similar (96.3 vs. 87.5 in NM vs. IM) (Figure S4). As shown in Figure 4, the MR_Metamizole:MR+Metamizole of NM and IM were comparable, indicating that the *6 genotype did not affect the inducibility of CYP2B6. Regarding CYP2C9, we found 5 NM (*1/*1), 3 heterozygous CYP2C9*2 carriers (*1/*2), and 3 heterozygous CYP2C9*3 carriers (*1/*3), both categorized as IM, and one homozygous CYP2C9*3 carrier, categorized as PM. Surprisingly, the subject with the highest MR was an NM and not, as expected, the only PM. The only PM among the subjects had unexpectedly one of the lowest MR (Figure S4), suggesting the presence of additional SNPs affecting the phenotype. As shown in Figure 4, the MR_Metamizole:MR+Metamizole ratios among NM, IM, and PM were not different, suggesting that the genotype did not affect the inducibility of CYP2C9. Genotyping of CYP2C19 revealed 7 NM (*1/*1), 2 heterozygous carriers of the CYP2C19*2 allele (*1/*2 and *2/*17) classified as IM and 3 heterozygous carriers of the CYP2C19*1/*17 variant classified as RM. Although not statistically significant due to the small number of subjects, we would not exclude the possibility that IM have impaired CYP2C19 inducibility (Figure 4). Regarding the effect on the basal MR, CYP2C19 IM had the highest and RM the lowest values but this difference did not reach statistical significance due to the small number of subjects investigated (Figure S4). Concerning CYP2D6, we found 9 NM (*1/*1, *1/*2, *2/*2, *1/*41 or *2/*41 diplotype, activity score 1.25–2.25) and 3 IM (*4/*10 or *29/*41 diplotype, activity score 0.25–1.00). The SNPs *10, *29, and *41 are associated with decreased CYP2D6 activity, and the *4 allele with no activity. As shown in Figure 4, the inducibility appeared not to be affected by metamizole.

**Mechanism of CYP induction**

We used differentiated HepaRG cells, which have a hepatocyte-like morphology and a similar expression and activity of most CYPs as human hepatocytes. As shown in Figure 5, treatment with 300 µM 4-MAA for 72 hours increased the mRNA content of CYP2B6, CYP2C9, CYP2C19, and CYP3A4 significantly (4.8-fold, 1.4-fold, 1.5-fold, and 2.0-fold, respectively), whereas CYP1A2 and CYP2D6 were unaffected. Incubation with 10 µM rifampicin, a PXR activator, resulted in an increased mRNA content of the same CYPs (CYP2B6 4.3-fold, CYP2C9 1.4-fold, CYP2C19 2.2-fold, and CYP3A4 6.0-fold), proving the functionality of the system. Co-incubation with metformin, an inhibitor of PXR and CAR mediated CYP induction, suppressed both 4-MAA and rifampicin-induced upregulation of CYP mRNAs. CYP2D6 mRNA expression was not significantly affected, whereas metformin also suppressed CYP1A2 mRNA expression, suggesting a negative effect on the aryl hydrocarbon receptor.

To further investigate the role of both CAR and PXR in 4-MAA mediated CYP induction, CAR-knockout, PXR-knockout, and control HepaRG cells (5-F cells) were treated for 72 hours with 300 µM 4-MAA and specific ligands for the respective nuclear receptors (CAR: 1 µM CITCO, and PXR: 10 µM rifampicin; Figure 6). In 5-F cells (corresponding to HepaRG wild type cells), 4-MAA showed the expected induction of the mRNA of CYP2B6, 2C9, 2C19, and 3A4. Surprisingly, CITCO not only induced the mRNA of CYP2B6 and 2C19 (the increases in CYP3A4 and 2C9 mRNA were not significant), but also of CYP1A2. Rifampicin increased the mRNA expression of CYP2C19 and 3A4, whereas the increases in the mRNA of CYP2B6 and 2C9 were not significant.
In HepaRG cells lacking CAR, 4-MAA exhibited only a minor CYP2C9 mRNA induction, whereas CITCO still induced CYP1A2, but no other CYPs. In HepaRG cells lacking PXR, 4-MAA induced mRNA expression of CYP2B6, 2C9, 2C19, and CYP3A4, whereas rifampicin showed no CYP induction. The results indicate that CAR expression is essential for CYP mRNA induction by 4-MAA.

**DISCUSSION**

Metamizole has been used as an analgesic drug for nearly a century in multiple regions of the world. So far, the potential that metamizole can induce CYP2B6 and CYP3A4 has been suggested in one in vitro investigation 15 and in 3 clinical studies.18–20 In one of these studies, Qin et al. found a significantly increased bupropion hydroxylation after 4 days of metamizole treatment in 16 healthy men,18 suggesting that metamizole induces CYP2B6 activity. The authors suspected CYP2B6 induction via an interaction with CAR because of the structural similarity of metamizole with phenobarbital and the concomitantly increased hydroxybupropion clearance. Metabolism of hydroxybupropion is UDP-glucuronosyltransferase dependent, whose induction depends on CAR.47 Some years earlier, Saussele et al. had observed increased expression and activity of CYP2B6 and CYP3A4 in human liver microsomes from patients treated with metamizole and confirmed induction of CYP2B6 and CYP3A4 by 4-MAA in primary human hepatocytes but reporter-gene assays failed to show a direct PXR or CAR activation by 4-MAA.15 Similar to Qin et al., they also suspected a phenobarbital-like mechanism of induction due to the structural similarity of metamizole and phenobarbital.15 Although phenobarbital is known to induce various CYPs via indirect activation of CAR,48 it has been shown recently that CYP3A4 induction by phenobarbital is mainly mediated via PXR.49 In support of the notion that metamizole can induce CYP2B6 and CYP3A4, Gaebler et al. reported decreased sertraline serum concentrations50 and Caraco et al. decreased cyclosporine blood concentrations in patients treated concomitantly with metamizole.19 Taken together, there was some evidence that metamizole induces CYP2B6 and CYP3A4 whereas information about induction of other CYPs and the mechanism of CYP induction was lacking. We therefore conducted a single center crossover study to assess the effect of metamizole treatment on six specific CYP substrates (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) using the cocktail approach.

We observed a significant decrease in the metabolic ratios for efavirenz, flurbiprofen, omeprazole, and midazolam, demonstrating a moderate induction of CYP2B6, 2C19, and 3A4, and a weak induction of CYP2C9. Although CYP2B6 and CYP3A4 upregulation due to metamizole are in line with the previously published studies,15,18,19,50 induction of CYP2C9 and CYP2C19 has so far not been reported. Surprisingly, we found a decreased metabolism of caffeine to paraxanthine by metamizole, indicating weak inhibition of CYP1A2. Because there is some evidence that CYP1A2 may be involved in the demethylation of 4-MAA,51 it is possible that the observed decrease in
CYP1A2 activity is the result of a competition between 4-MAA and caffeine.

We could not detect an impact of the genotype on the inducibility of CYP2B6, CYP2C9, and CYP2C19. However, these findings must be viewed with caution considering the limited number of subjects studied. Furthermore, with our genetic analysis we only assessed single nucleotide polymorphisms, but not the number of gene copies. Thus, we could have missed CYP2D6 UMs. Considering that we found no induction of CYP2D6, it is, however, unlikely that this omission has an impact on the interpretation of the results of this study.

To confirm the results of the clinical study, we performed in vitro experiments in HepaRG cells. After differentiation, this human hepatoma cell line has similar drug metabolizing properties as human hepatocytes. After 72 hours of treatment with 300 µM 4-MAA, we observed a significant increase in CYP2B6, CYP2C9, CYP2C19, and CYP3A4 mRNA, which confirmed the findings of our clinical study. Incubation of HepaRG cells with rifampicin showed upregulation of CYP2B6, CYP2C9, CYP2C19, and CYP3A4 mRNA, which confirmed the findings of our clinical study. Induction of CYP2B6, CYP2C9, and CYP2C19, and CYP3A4 mRNA by MAA and to a variable extent also by CITCO and rifampicin. To our surprise, CITCO also induced CYP1A2 in CAR knock-out and 5-F control cells, suggesting an interaction with the aryl hydrocarbon receptor. This phenomenon has been described in similar experiments before. Although PXR knock-out HepaRG cells showed a comparable upregulation of CYP2C9 and CYP2C19 mRNA and an even more extensive induction of CYP2B6 and CYP3A4 mRNA compared with the 5-F control cell line in the presence of 4-MAA, CAR knock-out HepaRG did not show a significant upregulation by 4-MAA, except for CYP2C9. The specific inducers CITCO and rifampicin showed no CYP mRNA induction in the absence of the nuclear factor that they activate. These results show that 4-MAA-derived induction of CYP2B6, 2C9, 2C19, and 3A4 is mediated via CAR activation. Our study does not answer the question, however, whether the induction via CAR is direct or indirect.

In conclusion, metamizole is a broad CYP inducer via its major metabolite 4-MAA, which interacts directly or indirectly with CAR. In addition, metamizole is an inhibitor of CYP1A2. Regarding the widespread use of this analgesic in some countries, particularly in the elderly with numerous comediations, these interactions are of major clinical relevance.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website (www.cpt-journal.com).

ACKNOWLEDGMENTS
The authors would like to thank our study nurses Claudia Bläsi and Joyce Jesus de Santos for their valuable help in study preparation and conduction.

FUNDING
The study was supported by a grant from the Swiss National Science foundation to M.H. and S.K. (SNF 31003A_156270).

CONFLICT OF INTEREST
S.K. gave talks in symposia sponsored by Sanofi. All other authors declared no competing interests for this work.

AUTHOR CONTRIBUTIONS
F.B., U.D., and S.K. wrote the manuscript. F.B. and S.K. designed the research. F.B., U.D., M.P., and H.M. performed the research. F.B., U.D., and S.K. analyzed the data. H.M., U.D., M.H., M.P., and J.H. contributed analytical tools.

© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

1. Blaser, L.S., Tramonti, A., Egger, P., Haschke, M., Krähenbühl, S. & Rätz Bravo, A.E. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur. J. Clin. Pharmacol. 71, 209–217 (2015).
2. Hoffmann, F., Meinecke, P., Freitag, M.H., Glaeske, G., Schulze, J. & Schmie mann, G. Who gets dipyrone (metamizole) in Germany? Prescribing by age, sex and region. J. Clin. Pharm. 40, 285–288 (2015).
3. Andrade, S.E., Martinez, C. & Walker, A.M. Comparative safety evaluation of non-narcotic analgesics. J. Clin. Epidemiol. 51, 1357–1365 (1998).
4. Sánchez, S., De La Lastra, C.A., Ortiz, P., Motilva, V. & Martín, M.J. Gastrointestinal tolerability of metamizol, acetaminophen, and diclofenac in subchronic treatment in rats. Dig. Dis. Sci. 47, 2791–2798 (2002).
5. Ergün, H., Frattarelli, D.A.C. & Aranda, J.V. Characterization of the role of physicochemical factors on the hydrolysis of dipyrone. J. Pharm. Biomed. Anal. 35, 479–487 (2004).
6. Noda, A., Goromaru, T., Tsubone, N., Matsuyama, K. & Iguchi, S. In vivo formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. I. Chem. Pharm. Bull. (Tokyo) 24, 1502–1505 (1976).
7. Noda, A., Tsubone, N., Mihara, M., Goromaru, T. & Iguchi, S. Formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. II. Enzymatic demethylation and oxidation of aminopyrine and 4-monomethylaminoantipyrine. Chem. Pharm. Bull. (Tokyo) 24, 3229–3231 (1976).
8. Volz, M. & Kellner, H.M. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br. J. Clin. Pharmacol. 10(suppl. 2), 2995–3085 (1980).
9. Levy Micha, Z.-K.E. & Bernd, R. Clinical pharmacokinetics of dipyrone and its metabolites. Clin. Pharmacokinet. 28, 216–234 (1995).
10. Zylber-Katz, E., Granit, L. & Levy, M. Formation and excretion of dipyrone metabolites in man. Eur. J. Clin. Pharmacol. 42, 187–191 (1992).
11. Flusser, D., Zylber-Katz, E., Granit, L. & Levy, M. Influence of food on the pharmacokinetics of dipyrone. Eur. J. Clin. Pharmacol. 34, 105–107 (1988).
12. Agundez, J.A., Martinez, C. & Benitez, J. Metabolism of aminopyrine and derivatives in man: in vivo study of polymorphic and polymorphic metabolic pathways. Xenobiotica 25, 417–427 (1995).
13. Geisslinger, G., Bocker, R. & Levy, M. High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharm. Res. 13, 1272–1275 (1996).
14. Bachmann, F., Duthaler, U., Rudin, D., Krähenbühl, S. & Haschke, M. N-demethylation of N-methyl-4-aminooantipyrine, the main metabolite of metamizole. Eur. J. Pharm. Sci. 120, 172–180 (2018).
15. Saussele, T. et al. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin. Pharmacol. Ther. 82, 265–274 (2007).
16. Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkana, J. & Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82, 667–715 (2008).
17. Hewitt, N.J., Lecluyse, E.L. & Ferguson, S.S. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37, 1196–1224 (2007).
18. Qin, W.J. et al. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br. J. Clin. Pharmacol. 74, 999–1004 (2012).
19. Caraco, Y., Zylber-Katz, E., Fridlander, M., Admon, D. & Levy, M. The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. Eur. J. Clin. Pharmacol. 55, 475–478 (1999).
20. Gea bler, A.J. et al. Metamizole but not bupropen reduces the plasma concentration of sertraline: implications for the concurrent treatment of pain and depression/anxiety disorders. Br. J. Clin. Pharmacol. https://doi.org/10.1111/bcp.14471. [e-pub ahead of print].
21. Zhou, H., Tong, Z. & McLeod, J.F. “Cocktail” approaches and strategies in drug development: valuable tool or flawed science? J. Clin. Pharmacol. 44, 120–134 (2004).
22. Derungs, A., Donzelli, M., Berger, B., Nopen, C., Krähenbühl, S. & Haschke, M. Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the Basel cocktail: a randomized crossover study. Clin. Pharmacokinet. 55, 79–91 (2016).
23. Donzelli, M. et al. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isofoms in plasma, saliva and dried blood spots. Clin. Pharmacokinet. 53, 271–282 (2014).
24. Camblin, M., Berger, B., Haschke, M., Krähenbühl, S., Huwyler, J. & Puchkov, M. CombiCap: a novel drug formulation for the Basel phenotyping cocktail. Int. J. Pharm. 512, 253–261 (2016).
25. Blaser, L. et al. Clinical safety of metamizole. 2016, PhD Thesis, University of Basel, Faculty of Science. http://edoc.unibas.ch/diss/DissB_11691
26. Blaser, L. et al. Leucopenia associated with metamizole: a case-control study. Swiss Med. Wkly. 147, w14438 (2017).
27. Vizeli, P., Schmid, Y., Prestin, K., Meyer zu Schwedissen, H.E. & Liechti, M.E. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur. Neuropsychopharmacol. 27, 232–238 (2017).
28. Schmid, Y., Vizeli, P., Hysek, C.M., Prestin, K., Meyer zu Schwedissen, H.E. & Liechti, M.E. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylenedioxyamphetamine in a controlled study in healthy individuals. Pharmacogenet. Genom. 26, 397–401 (2016).
29. Van Booven, D. et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genom. 20, 277–281 (2010).
30. Suenderhauf, C. et al. Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults. Br. J. Clin. Pharmacol. 86, 352–361 (2020).
31. Bachmann, F., Blaser, L., Haschke, M., Krähenbühl, S. & Duthaler, U. Development and validation of an LC-MS/MS method for
the bioanalysis of the major metamizole metabolites in human plasma. *Bioanalysis* **12**, 175–189 (2020).

32. Berger, B. *et al.* Comparison of liver cell models using the Basel phenotyping cocktail. *Front. Pharmacol.* **7**, 443 (2016).

33. Grunig, D., Felser, A., Bouitbir, J. & Krahenbuhl, S. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. *Toxicol. In Vitro* **42**, 337–347 (2017).

34. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F. & Guguen-Guillouzo, C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem. Biol. Interact.* **168**, 66–73 (2007).

35. Quiros, P.M., Goyal, A., Jha, P. & Auwerx, J. Analysis of mtDNA/nDNA ratio in mice. *Curr. Protocols Mouse Biol.* **7**, 47–54 (2017).

36. Spraul, M., Hofmann, M., Wilson, I.D., Lenz, E., Nicholson, J.K. & Lindon, J.C. Coupling of HPLC with 19F- and 1H-NMR spectroscopy to investigate the human urinary excretion of flurbiprofen metabolites. *J. Pharm. Biomed. Anal.* **11**, 1009–1015 (1993).

37. Berger, B., Bachmann, F., Duthaler, U., Krahenbuhl, S. & Haschke, M. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. *Front. Pharmacol.* **9**, 774 (2018).

38. Wang, L., Hu, Z., Deng, X., Wang, Y., Zhang, Z. & Cheng, Z.N. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. *Basic Clin. Pharmacol. Toxicol.* **112**, 257–263 (2013).

39. Nyakutira, C. *et al.* High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. *Eur. J. Clin. Pharmacol.* **64**, 357–365 (2008).

40. Santos, P.C. *et al.* CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. *BMC Med. Genet.* **12**, 13 (2011).

41. Crews, K.R. *et al.* Clinical pharmacogenetics implementation consortium (CPLIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin. Pharmacol. Ther.* **91**, 321–326 (2012).

42. Hicks, J.K. *et al.* Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin. Pharmacol. Ther.* **98**, 127–134 (2015).

43. Hicks, J.K. *et al.* Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. *Clin. Pharmacol. Ther.* **93**, 402–408 (2013).

44. Fuhr, U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. *Clin. Pharmacokinet.* **38**, 493–504 (2000).

45. Krausova, L. *et al.* Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. *Biochem. Pharmacol.* **82**, 1771–1780 (2011).

46. Nebert, D.W., Dalton, T.P., Okey, A.B. & Gonzalez, F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. *J. Biol. Chem.* **279**, 23847–23850 (2004).

47. Tolson, A.H. & Wang, H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. *Adv. Drug Deliv. Rev.* **62**, 1238–1249 (2010).

48. Corcos, L. & Lagadic-Gossmann, D. Gene induction by Phenobarbital: an update on an old question that receives key novel answers. *Pharmacol. Toxicol.* **89**, 113–122 (2001).

49. Li, L. *et al.* Mechanistic insights of phenobarbital-mediated activation of human but not mouse pregnane X receptor. *Mol. Pharmacol.* **96**, 345–354 (2019).

50. Kraul, H. *et al.* Immunohistochemical properties of dipyramine-induced cytochromes P450 in rats. *Hum. Exp. Toxicol.* **15**, 45–50 (1996).

51. Blanco, G., Martínez, C., García-Martín, E. & Agüinde, J.A.G. Cytochrome P450 gene polymorphisms and variability in response to NSAIDs. *Clin. Res. Regul. Affairs* **22**, 57–81 (2005).

52. Chai, S.C., Cherian, M.T., Wang, Y.M. & Chen, T. Small-molecule modulators of PXR and CAR. *Biochim. Biophys. Acta 1859*, 1141–1154 (2016).

53. Li, D. *et al.* Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells. *Biochem. Pharmacol.* **98**, 190–202 (2015).